Gryphon Sciences Company Profile

06:09 EST 22nd November 2017 | BioPortfolio

Gryphon can generate novel or improved protein therapeutics using chemistry alone. This positions Gryphon to benefit from the revolution in genomics and proteomics that has identified countless new potential protein therapeutics.

Gryphon uses two technologies that allow it to rapidly produce proteins of medical interest. These technologies form a powerful drug development platform, which Gryphon has used to address large commercial markets. Our products combine chemically synthesized protein backbones with precision length polymers (PLPs) to create potent medications. The use of chemistry, rather than biology, allows us to manipulate protein drugs in ways that were never before possible. Gryphon has introduced changes to the molecules, which result in their increased potency, and duration in the circulatory system. Efficient-scalable processes with high yields make this a cost effective way to manufacture valuable drugs.


250 E. Grand Avenue Suite 90
South San Francisco
United States of America


Phone: 415 952 7714
Fax: 415 952 3055

News Articles [245 Associated News Articles listed on BioPortfolio]

Gryphon Investors’ CORA Health Services Expands into Georgia

Completes Five Add-on Acquisitions of Five Physical Therapy Companies In 2017 CORA Health Services, Inc. (“CORA”), a top 10 national operator of outpatient physical...

Gryphon Investors To Acquire Ob Hospitalist Group from Ares Management

Gryphon Investors (“Gryphon”), a San Francisco-based private equity firm, and Ares Management, L.P. (“Ares”) (NYSE:ARES) today announced that Gryphon will acquire Ob Hospi...

CV Sciences, Inc. Announces Webcast for Investor Update Call

LAS VEGAS, NV--(Marketwired - September 11, 2017) -CV Sciences, Inc., ( OTCQB : CVSI) (the "Company," "CV Sciences," "our" or "we") Read more...

CV Sciences, Inc. to Present at MJAC2017 InvestorsHub International Cannabis Conference

LAS VEGAS, NV--(Marketwired - August 28, 2017) -CV Sciences, Inc. ( OTCQB : CVSI) ("CV Sciences," "our" or "we"), is pleased to Read more...

CV Sciences, Inc. Highlights Recent Research Showing Cannabidiol May Reduce Relapses in ...

LAS VEGAS, NV--(Marketwired - August 15, 2017) -CV Sciences, Inc.( OTCQB : CVSI) (the "Company," "CV Sciences," "our" or "we") highlighted Read more...

Almac Sciences: Company Activity and Sharing Risks in Collaborations

In this episode of PharmaTelevision News Review, Fintan Walton talks with Denis Geffroy, Vice President Business Development at Almac Sciences at Almac. Filmed at BioTrinity 2010 in Newbury, UK, they ...

Super Saver Rate Ending for San Diego Life Sciences 2022 on December 11

When Xconomy gathered a handful of life sciences visionaries in 2010 to predict what the local life sciences landscape would look like in 2030, biotech CEO John Mendlein talked about the intertwining ...

Lords Committee Launches New Inquiry into Life Sciences and the Industrial Strategy

The House of Lords Science and Technology Committee invites contributions to its new inquiry - Life Sciences and the Industrial Strategy. The Government set out in its Industrial Strategy Green Paper ...

Clinical Trials [156 Associated Clinical Trials listed on BioPortfolio]

M-learning to Improve Professional Competencies in Health Sciences

The aim of this study is to investigate whether a mobile application is useful for improving knowledge about professional competencies in students enrolled in Health Sciences degrees.

Cognitive Rehabilitation With C8 Sciences

C8 sciences program is a cognitive training program mainly developed for the students, and the effectiveness is well established. The aim of this trial is to assess clinical efficacy of th...

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus S...

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

Companies [1026 Associated Companies listed on BioPortfolio]

Gryphon Sciences

Gryphon can generate novel or improved protein therapeutics using chemistry alone. This positions Gryphon to benefit from the revolution in genomics and proteomics that has identified countless new po...

Gryphon Investors

Based in San Francisco, Gryphon Investors focuses on leveraged acquisitions of, and growth investments in, middle-market companies in partnership with experienced management. Havi...

Gryphon House, Inc.

Gryphon House, Inc., is an award-winning publisher of resource books for parents and teachers of children from birth through age eight. Developmentally appropriate and easy...

DVS Sciences, Inc.

DVS Sciences is a life sciences technology company that has developed and manufactures a novel technology for highly multiplexed analysis of single cells. DVS Sciences has an R&D ...

Origin Sciences Limited

Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based i...

More Information about "Gryphon Sciences" on BioPortfolio

We have published hundreds of Gryphon Sciences news stories on BioPortfolio along with dozens of Gryphon Sciences Clinical Trials and PubMed Articles about Gryphon Sciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gryphon Sciences Companies in our database. You can also find out about relevant Gryphon Sciences Drugs and Medications on this site too.

Quick Search

Relevant Topic

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record